Rick Gonzalez, AbbVie CEO (Pablo Martinez Monsivais/AP Images)
April 29, 2022 01:26 PM EDTUpdated 03:01 PM
Pharma

Ab­b­Vie toss­es its triplet ther­a­py for cys­tic fi­bro­sis, leav­ing Ver­tex to reign supreme

Nicole DeFeudis

Editor

Ab­b­Vie went all in on cys­tic fi­bro­sis a few years ago, shelling out $245 mil­lion for a port­fo­lio of drugs from Gala­pa­gos in the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Pfiz­er CEO says op­por­tu­ni­ties with Trump ‘clear­ly out­weigh’ the risks for phar­ma

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times